PE20030845A1 - Compuestos de espiro-hidantoina utiles como agentes anti-inflamatorios - Google Patents
Compuestos de espiro-hidantoina utiles como agentes anti-inflamatoriosInfo
- Publication number
- PE20030845A1 PE20030845A1 PE2002000971A PE2002000971A PE20030845A1 PE 20030845 A1 PE20030845 A1 PE 20030845A1 PE 2002000971 A PE2002000971 A PE 2002000971A PE 2002000971 A PE2002000971 A PE 2002000971A PE 20030845 A1 PE20030845 A1 PE 20030845A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- diazaespiro
- diona
- bromophenyl
- dichlorophenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/96—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
Abstract
SE REFIERE A ESPIRO-HIDANTOINAS DE FORMULA I DONDE: L Y K SON O, S; Z ES N, CR4b, Ar ES ARILO, HETEROARILO, G ESTA UNIDO AL ANILLO A EN T, M, SI SE UNE AL CARBONO DEL ANILLO A ES O, N, S, ALQUILENO, ALCOXI, ENTRE OTROS; SI SE UNE AL NITROGENO DEL ANILLO A G ES ENLACE, ALQUILENO, ACILO, ENTRE OTROS; J ES O, S, NR3, N, S, SO2, O ESTA AUSENTE, ENTRE OTROS; T ES T1 CUANDO G-Ar ESTA UNIDO A T; T ES T2 CUANDO G-Ar ESTA UNIDO A M; M ES M1, CUANDO G-Ar ESTA UNIDO A M; M ES M2 CUANDO G-Ar ESTA UNIDO A T; T1 Y M1 ES N, CR5; T2, M2 ES O, S, NR6, SO, SO2, ENTRE OTROS; R2 ES H, ALQUILO, OR12, NR12R13, SOpR13a ENTRE OTROS; R4a, R4b, R4c SON H, HALOGENO, ALQUILO, ALQUENILO, NITRO, ENTRE OTROS; R3 Y R6 SON H, ALQUILO, HIDROXI, ALCOXI, ENTRE OTROS; R5, R7, R8 SON H, ALQUILO, HALOGENO, NITRO, ENTRE OTROS; R12 Y R13 SON H, ALQUILO, ARILO, ENTRE OTROS; p ES 1-2. SON COMPUESTOS PREFERIDOS (5R*,6S*)-6-(4-BROMOFENIL)-3-(3,5-DICLOROFENIL)-1-METIL-1,3-DIAZAESPIRO[4,4]NONAN-2,4-DIONA; (1S*,4R*-1-(4-BROMOFENIL)-7-(3,5-DICLOROFENIL)-5-METIL-5,7-DIAZAESPIRO[3,4]OCTAN-6,8-DIONA; (5R*,6S*)-6-(4-BROMOFENIL)-3-(3,5-DICLOROFENIL)-1-METIL-1,3-DIAZAESPIRO[4,5]DECAN-2,4-DIONA; ENTRE OTROS. TAMBIEN SE REFIERE A COMPUESTOS INTERMEDIARIOS. LOS COMPUESTOS SON INHIBIDORES DE ANTIGENO 1 ASOCIADO A FUNCION DE LINFOCITO (LFA-1) Y MOLECULA DE ADHESION INTERCELULAR (ICAM) Y PUEDE SER UTIL PARA EL TRATAMIENTO DE PADECIMIENTO ANTIINFLAMATORIO COMO HIPOGONADISMO, DEBILIDAD, OSTEOPOROSIS, DISFUNCION SEXUAL, DESGASTE, ANEMIA
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32636101P | 2001-10-01 | 2001-10-01 | |
US35411302P | 2002-02-04 | 2002-02-04 | |
US40025902P | 2002-08-01 | 2002-08-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20030845A1 true PE20030845A1 (es) | 2003-10-23 |
Family
ID=27406458
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2002000971A PE20030845A1 (es) | 2001-10-01 | 2002-10-01 | Compuestos de espiro-hidantoina utiles como agentes anti-inflamatorios |
Country Status (24)
Country | Link |
---|---|
US (4) | US6977267B2 (es) |
EP (1) | EP1432700B1 (es) |
JP (1) | JP4394442B2 (es) |
KR (1) | KR20040041649A (es) |
CN (1) | CN1596253A (es) |
AR (1) | AR036663A1 (es) |
AT (1) | ATE447565T1 (es) |
BR (1) | BR0213025A (es) |
CA (1) | CA2462112A1 (es) |
DE (1) | DE60234264D1 (es) |
ES (1) | ES2339107T3 (es) |
GE (1) | GEP20063767B (es) |
HK (1) | HK1063467A1 (es) |
HR (1) | HRP20040311A2 (es) |
HU (1) | HUP0402338A3 (es) |
IL (1) | IL160990A0 (es) |
IS (1) | IS7197A (es) |
MX (1) | MXPA04002993A (es) |
NO (1) | NO20041339L (es) |
NZ (1) | NZ531870A (es) |
PE (1) | PE20030845A1 (es) |
PL (1) | PL369337A1 (es) |
RS (1) | RS26604A (es) |
WO (1) | WO2003029245A1 (es) |
Families Citing this family (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1894234A (zh) * | 2003-03-25 | 2007-01-10 | 武田药品工业株式会社 | 二肽基肽酶抑制剂 |
EP1615698B1 (en) * | 2003-04-11 | 2010-09-29 | High Point Pharmaceuticals, LLC | New amide derivatives and pharmaceutical use thereof |
US7700583B2 (en) | 2003-04-11 | 2010-04-20 | High Point Pharmaceuticals, Llc | 11β-hydroxysteroid dehydrogenase type 1 active compounds |
US7678909B1 (en) | 2003-08-13 | 2010-03-16 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US7169926B1 (en) | 2003-08-13 | 2007-01-30 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
MXPA06001601A (es) * | 2003-08-13 | 2006-08-25 | Takeda Pharmaceutical | Derivados de 4-pirimidona y su uso como inhibidores de dipeptidilpeptidasa. |
US20050065144A1 (en) * | 2003-09-08 | 2005-03-24 | Syrrx, Inc. | Dipeptidyl peptidase inhibitors |
WO2005026148A1 (en) * | 2003-09-08 | 2005-03-24 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
US7199125B2 (en) | 2003-10-02 | 2007-04-03 | Bristol-Myers Squibb Company | Spiro-cyclic compounds useful as anti-inflammatory agents |
EP1682537B1 (en) | 2003-11-05 | 2012-03-28 | SARcode Bioscience Inc. | Modulators of cellular adhesion |
DE602004031881D1 (de) | 2003-12-19 | 2011-04-28 | Univ California | Verfahren und materialien zur beurteilung von prostatakrebstherapien |
NZ550102A (en) | 2004-02-24 | 2010-10-29 | Univ California | Methods and materials for assessing prostate cancer therapies and compounds (thiohydantoine derivatives) |
US7732446B1 (en) | 2004-03-11 | 2010-06-08 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
CN102079743B (zh) * | 2004-03-15 | 2020-08-25 | 武田药品工业株式会社 | 二肽基肽酶抑制剂 |
WO2005118555A1 (en) * | 2004-06-04 | 2005-12-15 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
CN1976938B (zh) | 2004-07-01 | 2012-08-15 | 第一三共株式会社 | 具有pde7抑制活性的噻吩并吡唑衍生物 |
WO2006019965A2 (en) | 2004-07-16 | 2006-02-23 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
US7375237B2 (en) | 2004-08-18 | 2008-05-20 | Bristol-Myers Squibb Company | Pyrrolizine compounds useful as anti-inflammatory agents |
TW200616634A (en) * | 2004-10-01 | 2006-06-01 | Bristol Myers Squibb Co | Crystalline forms and process for preparing spiro-hydantoin compounds |
CA2585797C (en) * | 2004-11-10 | 2015-01-06 | Incyte Corporation | Lactam compounds and their use as pharmaceuticals |
US8110581B2 (en) * | 2004-11-10 | 2012-02-07 | Incyte Corporation | Lactam compounds and their use as pharmaceuticals |
US20060142319A1 (en) * | 2004-12-14 | 2006-06-29 | Bang-Chi Chen | Pyridyl-substituted spiro-hydantoin crystalline forms and process |
US7186727B2 (en) * | 2004-12-14 | 2007-03-06 | Bristol-Myers Squibb Company | Pyridyl-substituted spiro-hydantoin compounds and use thereof |
WO2006068978A2 (en) * | 2004-12-21 | 2006-06-29 | Takeda Pharmaceutial Company Limited | Dipeptidyl peptidase inhibitors |
US20090117197A1 (en) * | 2005-03-21 | 2009-05-07 | Vicus Therapeutics Llc | Compositions and methods for ameliorating cachexia |
US20080033027A1 (en) * | 2005-03-21 | 2008-02-07 | Vicus Therapeutics Spe 1, Llc | Drug combination pharmaceutical compositions and methods for using them |
US20090215852A1 (en) * | 2005-03-21 | 2009-08-27 | Chroma Group, Inc. | Compositions and methods for ameliorating cachexia |
US7709517B2 (en) | 2005-05-13 | 2010-05-04 | The Regents Of The University Of California | Diarylhydantoin compounds |
WO2007027532A2 (en) * | 2005-08-29 | 2007-03-08 | Merck & Co., Inc. | Niacin receptor agonists, compositions containing such compounds and methods of treatment |
WO2007033350A1 (en) | 2005-09-14 | 2007-03-22 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors for treating diabetes |
PL1931350T5 (pl) * | 2005-09-14 | 2021-11-15 | Takeda Pharmaceutical Company Limited | Podanie inhibitorów dipeptydylo-peptydazy |
TW200745080A (en) * | 2005-09-16 | 2007-12-16 | Takeda Pharmaceuticals Co | Polymorphs of tartrate salt of 2-[2-(3-(R)-amino-piperidin-1-yl)-5-fluoro-6-oxo-6H-pyrimidin-1-ylmethyl]-benzonitrile and methods of use therefor |
TW200745079A (en) * | 2005-09-16 | 2007-12-16 | Takeda Pharmaceuticals Co | Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor |
EP1924567B1 (en) * | 2005-09-16 | 2012-08-22 | Takeda Pharmaceutical Company Limited | Process for the preparation of pyrimidinedione derivatives |
BRPI0617271A2 (pt) * | 2005-10-11 | 2011-07-19 | Intermune Inc | inibidores de replicação viral |
US8926990B2 (en) * | 2009-10-13 | 2015-01-06 | Rutgers, The State University Of New Jersey | Treatment and diagnosis of inflammatory disorders and HIV |
CN101032483B (zh) * | 2006-03-09 | 2011-05-04 | 陈德桂 | 调节雄激素受体活性的乙内酰脲衍生物及其应用 |
DK2368550T3 (da) | 2006-03-27 | 2013-09-30 | Univ California | Androgenreceptormodulator til behandlingen af prostatakræft og androgenreceptor-associerede sygdomme |
JP2009531456A (ja) * | 2006-03-28 | 2009-09-03 | 武田薬品工業株式会社 | (r)−3−アミノピペリジン二塩酸塩の調製 |
WO2007112347A1 (en) | 2006-03-28 | 2007-10-04 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
EP2439196A1 (en) | 2006-03-29 | 2012-04-11 | The Regents of The University of California | Diarylthiohydantoin compounds for use in a method for the treatment of a hyperproliferative disorder |
US7740064B2 (en) | 2006-05-24 | 2010-06-22 | Baker Hughes Incorporated | System, method, and apparatus for downhole submersible pump having fiber optic communications |
AU2007288245A1 (en) | 2006-08-24 | 2008-02-28 | Novartis Ag | 2- (pyrazin-2-yl) -thiazole and 2- (1h-pyrazol-3-yl) -thiazole derivatives as well as related compounds as stearoyl-CoA desaturase (SCD) inhibitors for the treatment of metabolic, cardiovascular and other disorders |
US8324383B2 (en) | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
CA2663279C (en) * | 2006-09-13 | 2016-05-17 | Takeda Pharmaceutical Company Limited | Use of 2-6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-ylmethyl-4-fluoro-benzonitrile for treating diabetes, cancer, autoimmune disorders and hiv infection |
WO2008036715A1 (en) | 2006-09-22 | 2008-03-27 | Novartis Ag | Heterocyclic organic compounds |
TW200838536A (en) * | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
CN101595105B (zh) | 2006-12-20 | 2013-01-23 | 诺瓦提斯公司 | 作为scd抑制剂的2-取代的5元杂环化合物 |
EP2128163A1 (en) * | 2007-01-25 | 2009-12-02 | Takeda Pharmaceutical Company Limited | Spiro-ring compound |
WO2008096746A1 (ja) * | 2007-02-06 | 2008-08-14 | Takeda Pharmaceutical Company Limited | スピロ化合物およびその用途 |
US8093236B2 (en) | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
EP2172459B1 (en) * | 2007-07-19 | 2014-03-19 | Tokuyama Corporation | Compound having hydantoin ring and method of producing the same |
US20090155176A1 (en) | 2007-10-19 | 2009-06-18 | Sarcode Corporation | Compositions and methods for treatment of diabetic retinopathy |
UY31432A1 (es) | 2007-10-26 | 2009-05-29 | Compuestos de diarilhidantoina | |
US20090170770A1 (en) * | 2007-11-06 | 2009-07-02 | Ali Hafezi-Moghadam | Methods and compositions for treating conditions associated with angiogenesis using a vascular adhesion protein-1 (vap 1) inhibitor |
EP2445914B1 (en) | 2009-06-02 | 2015-07-22 | Boehringer Ingelheim International GmbH | DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-a]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES |
CN102740699A (zh) | 2009-09-04 | 2012-10-17 | 范德比尔特大学 | 用于治疗神经学上的功能失调的mglur4变构增效剂、组合物和方法 |
SG10201501202TA (en) | 2010-02-16 | 2015-04-29 | Aragon Pharmaceuticals Inc | Androgen Receptor Modulators And Uses Thereof |
ES2779748T3 (es) | 2012-08-23 | 2020-08-19 | Janssen Biopharma Inc | Compuestos para el tratamiento de infecciones víricas por paramixovirus |
ES2836424T3 (es) | 2012-09-26 | 2021-06-25 | Aragon Pharmaceuticals Inc | Antiandrógenos para tratar el cáncer de próstata no metastásico y resistente a la castración |
JOP20200097A1 (ar) | 2013-01-15 | 2017-06-16 | Aragon Pharmaceuticals Inc | معدل مستقبل أندروجين واستخداماته |
AU2014308991B2 (en) | 2013-08-21 | 2019-02-14 | Janssen Biopharma, Inc. | Antiviral compounds |
MX2016013049A (es) * | 2014-04-04 | 2017-04-27 | X-Rx Inc | Inhibidores de autotaxina espirociclicos sustituidos. |
ES2838573T3 (es) | 2014-08-21 | 2021-07-02 | Bristol Myers Squibb Co | Derivados de benzamida ligados como inhibidores potentes de ROCK |
MA41614A (fr) | 2015-02-25 | 2018-01-02 | Alios Biopharma Inc | Composés antiviraux |
TWI726969B (zh) | 2016-01-11 | 2021-05-11 | 比利時商健生藥品公司 | 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物 |
WO2017170830A1 (ja) * | 2016-03-31 | 2017-10-05 | 武田薬品工業株式会社 | 複素環化合物 |
EP3697398A1 (en) | 2017-10-16 | 2020-08-26 | Aragon Pharmaceuticals, Inc. | Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer |
JP2024502909A (ja) * | 2020-12-24 | 2024-01-23 | アルマルソン、オーン | キサントフィル誘導体 |
CN115536494B (zh) * | 2022-10-31 | 2023-12-01 | 苏州诚和医药化学有限公司 | 1-(4-溴苯基)-1,4-丁二醇的合成方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1331757C (en) * | 1988-02-29 | 1994-08-30 | Janssen Pharmaceutica Naamloze Vennootschap | 5-lipoxygenase inhibiting 4-(4-phenyl-1-piperazinyl)phenols |
US5346913A (en) * | 1992-05-26 | 1994-09-13 | Rohm And Haas Company | N-iodopropargyl hydantoin compounds, compositions, preparation, and use as antimicrobial agents |
FR2694290B1 (fr) * | 1992-07-08 | 1994-09-02 | Roussel Uclaf | Nouvelles phénylimidazolidines éventuellement substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant. |
TW521073B (en) * | 1994-01-05 | 2003-02-21 | Hoechst Marion Roussel Inc | New optionally substituted phenylimidazolidines, their preparation process, their use as anti-androgenic agent and the pharmaceutical compositions containing them |
FR2741342B1 (fr) * | 1995-11-22 | 1998-02-06 | Roussel Uclaf | Nouvelles phenylimidazolidines fluorees ou hydroxylees, procede, intermediaires de preparation, application comme medicaments, nouvelle utilisation et compositions pharmaceutiques |
ES2333412T3 (es) | 2001-05-25 | 2010-02-22 | Bristol-Myers Squibb Company | Derivados de hidantoina como inhibidores de metaloproteinasas de matriz. |
-
2002
- 2002-09-30 CN CNA028238540A patent/CN1596253A/zh active Pending
- 2002-09-30 NZ NZ531870A patent/NZ531870A/en unknown
- 2002-09-30 MX MXPA04002993A patent/MXPA04002993A/es unknown
- 2002-09-30 AT AT02800414T patent/ATE447565T1/de not_active IP Right Cessation
- 2002-09-30 ES ES02800414T patent/ES2339107T3/es not_active Expired - Lifetime
- 2002-09-30 IL IL16099002A patent/IL160990A0/xx unknown
- 2002-09-30 HU HU0402338A patent/HUP0402338A3/hu unknown
- 2002-09-30 DE DE60234264T patent/DE60234264D1/de not_active Expired - Lifetime
- 2002-09-30 AR ARP020103695A patent/AR036663A1/es unknown
- 2002-09-30 CA CA002462112A patent/CA2462112A1/en not_active Abandoned
- 2002-09-30 JP JP2003532494A patent/JP4394442B2/ja not_active Expired - Fee Related
- 2002-09-30 BR BR0213025-4A patent/BR0213025A/pt not_active IP Right Cessation
- 2002-09-30 PL PL02369337A patent/PL369337A1/xx not_active Application Discontinuation
- 2002-09-30 WO PCT/US2002/031283 patent/WO2003029245A1/en active IP Right Grant
- 2002-09-30 GE GE5595A patent/GEP20063767B/en unknown
- 2002-09-30 KR KR10-2004-7004778A patent/KR20040041649A/ko not_active Application Discontinuation
- 2002-09-30 RS YU26604A patent/RS26604A/sr unknown
- 2002-09-30 EP EP02800414A patent/EP1432700B1/en not_active Expired - Lifetime
- 2002-10-01 US US10/262,182 patent/US6977267B2/en not_active Expired - Lifetime
- 2002-10-01 PE PE2002000971A patent/PE20030845A1/es not_active Application Discontinuation
-
2004
- 2004-03-24 IS IS7197A patent/IS7197A/is unknown
- 2004-03-31 NO NO20041339A patent/NO20041339L/no not_active Application Discontinuation
- 2004-04-01 HR HR20040311A patent/HRP20040311A2/hr not_active Application Discontinuation
- 2004-05-24 US US10/852,576 patent/US7078420B2/en not_active Expired - Lifetime
- 2004-06-16 US US10/869,289 patent/US20040259897A1/en not_active Abandoned
- 2004-06-16 US US10/869,292 patent/US20050004153A1/en not_active Abandoned
- 2004-08-18 HK HK04106189.4A patent/HK1063467A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP1432700A4 (en) | 2004-12-22 |
US6977267B2 (en) | 2005-12-20 |
IS7197A (is) | 2004-03-24 |
NO20041339L (no) | 2004-05-24 |
MXPA04002993A (es) | 2004-07-15 |
US20040009998A1 (en) | 2004-01-15 |
DE60234264D1 (de) | 2009-12-17 |
RS26604A (en) | 2006-12-15 |
ES2339107T3 (es) | 2010-05-17 |
ATE447565T1 (de) | 2009-11-15 |
US7078420B2 (en) | 2006-07-18 |
US20050004153A1 (en) | 2005-01-06 |
IL160990A0 (en) | 2004-08-31 |
CN1596253A (zh) | 2005-03-16 |
AR036663A1 (es) | 2004-09-22 |
NZ531870A (en) | 2005-08-26 |
JP2005510476A (ja) | 2005-04-21 |
HUP0402338A3 (en) | 2008-10-28 |
BR0213025A (pt) | 2004-10-05 |
WO2003029245A1 (en) | 2003-04-10 |
HUP0402338A2 (hu) | 2005-02-28 |
KR20040041649A (ko) | 2004-05-17 |
EP1432700A1 (en) | 2004-06-30 |
US20040248920A1 (en) | 2004-12-09 |
HK1063467A1 (en) | 2004-12-31 |
CA2462112A1 (en) | 2003-04-10 |
HRP20040311A2 (en) | 2005-02-28 |
JP4394442B2 (ja) | 2010-01-06 |
GEP20063767B (en) | 2006-03-10 |
NO20041339D0 (no) | 2004-03-31 |
PL369337A1 (en) | 2005-04-18 |
EP1432700B1 (en) | 2009-11-04 |
US20040259897A1 (en) | 2004-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20030845A1 (es) | Compuestos de espiro-hidantoina utiles como agentes anti-inflamatorios | |
PE20030292A1 (es) | Compuestos de heteroarilo biciclicos fusionados substituidos con heteroarilo como ligandos del receptor gabaa | |
PE20060586A1 (es) | DERIVADOS DE PIRAZOLO [1,5-a]PIRIMIDINA COMO ANTAGONISTAS DEL RECEPTOR CRF | |
PE20070407A1 (es) | Compuestos derivados de pirazina como antagonistas del receptor a2b de adenosina | |
PE20060623A1 (es) | Compuestos de sulfonamida como potenciadores del receptor de glutamato | |
PE20110834A1 (es) | DERIVADOS DE PIRROL[3,4-d]PIRIMIDINA COMO INHIBIDORES DE FOSFODIESTERASA 1 (PDE1) | |
PE20060625A1 (es) | Derivados de benzazepina como antagonistas y/o agonistas del receptor h3 de histamina | |
PE20040934A1 (es) | Derivados de pirimidina como inhibidores selectivos de tirosina quinasas | |
AR004320A1 (es) | Nuevos compuestos de pirimidina condensados biciclicos; un procedimiento para su preparacion; composiciones farmaceuticas que los contienen y su usocomo agentes terapeuticos, en particular como inhibidores de la tirosina quinasa. | |
PE20010629A1 (es) | Derivados de triazolpiridinamina como ligandos de receptores de adenosina | |
PE20060185A1 (es) | ANTAGONISTA DEL RECEPTOR A2A DE LA ADENOSINA CON ESTRUCTURA DE PIRAZOLO--[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PIRIMIDINA | |
PE20030940A1 (es) | Derivados de piridina y pirimidina | |
PE20010854A1 (es) | USO DE DERIVADOS DE PIRIMIDINA 4 SUSTITUIDOS COMO ANTAGONISTAS DE LOS RECEPTORES DE GLUTAMATO mGluR1 | |
PE20060653A1 (es) | Derivados triciclicos condensados como moduladores del receptor 5-ht1 | |
EA199800478A1 (ru) | N-([1,2,4]триазолазинил)бензолсульфонамиды и пиридинсульфонамиды и их применение в качестве гербицидов | |
ATE384050T1 (de) | Benzazepinderivate als histamin-h3-antagonisten | |
PE20030415A1 (es) | Derivados policiclicos de guanina como inhibidores de fosfodiesterasa v | |
DE60326060D1 (de) | Nichtvernetzende pyrroloä2,1-cüä1,4übenzodiazepine als potentielle antitumor-agentien und ihre herstellung | |
PE20030922A1 (es) | Derivados de piridina y quinolina | |
PE120999A1 (es) | Piridinas, piridazinas, pirimidinas y pirazinas biciclicas | |
PE20011305A1 (es) | Agentes diazabiciclicos activos en el snc | |
PE20060873A1 (es) | Compuestos de quinolina heteroaromaticos | |
KR20150036358A (ko) | E1 활성화 효소의 억제제로서 유용한 헤테로아릴 화합물 | |
PE20060531A1 (es) | Derivados de piridazin-3-(2h)-ona como inhibidores de la fosfodiesterasa 4 | |
UY27055A1 (es) | Activadores heteroaromaticos fusionados de la glucoquinasa |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |